Skip to main content
PMC home page
Annals of Surgery logoLink to Annals of Surgery
. 1995 Jul;222(1):78–86. doi: 10.1097/00000658-199507000-00013

Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene.

W R Smythe 1, H C Hwang 1, A A Elshami 1, K M Amin 1, S L Eck 1, B L Davidson 1, J M Wilson 1, L R Kaiser 1, S M Albelda 1
PMCID: PMC1234759  PMID: 7618973

Abstract

OBJECTIVE: The authors demonstrate the ability of an adenovirus vector expressing the herpes simplex thymidine kinase (HSVtk) gene to treat human malignant mesothelioma growing within the peritoneal cavity of severe combined immunodeficient (SCID) mice. BACKGROUND DATA: Introduction of the HSVtk gene into tumor cells renders them sensitive to the antiviral drug ganciclovir (GCV). This approach has been used previously to treat experimental brain tumors. Although malignant mesothelioma is refractory to current therapies, its localized nature and the accessibility of the pleural space make it a potential target for a similar type of in vivo gene therapy using adenovirus. METHODS: An adenovirus containing the HSVtk gene (Ad.RSVtk) was used to transduce mesothelioma cells in vitro. These cells were then injected into the flanks of SCID mice. Ad.RSVtk was also injected directly into the peritoneal cavity of SCID mice with established human mesothelioma tumors. Mice were subsequently treated for 7 days with GCV at a dose of 5 mg/kg. RESULTS: Mesothelioma cells transduced in vitro with Ad.RSVtk formed nodules when injected in the subcutaneous tissue. These tumors could be eliminated by the administration of GCV, even when as few as 10% of cells were transduced to express HSVtk (bystander effect). Administration of Ad.RSVtk into the peritoneal space of animals with established multifocal human mesothelioma followed by GCV therapy resulted in the eradication of macroscopic tumor in 90% of animals and microscopic tumor in 80% of animals when evaluated after 30 days. The median survival of animals treated with Ad.RSVtk/GCV was significantly longer than that of control animals treated with similar protocols. CONCLUSION: These results indicate that an adenoviral vector containing the HSVtk gene is effective in treating established malignant mesothelioma in an in vivo setting and raise the possibility of using adenovirus transfer of HSVtk for clinical trials in mesothelioma and other localized tumors.

Full text

PDF
82

Images in this article

83Figure 2.,Figure 3.
on p.83

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barba D., Hardin J., Sadelain M., Gage F. H. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci U S A. 1994 May 10;91(10):4348–4352. doi: 10.1073/pnas.91.10.4348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Berkner K. L. Development of adenovirus vectors for the expression of heterologous genes. Biotechniques. 1988 Jul-Aug;6(7):616–629. [PubMed] [Google Scholar]
  3. Bonnekoh B., Greenhalgh D. A., Bundman D. S., Eckhardt J. N., Longley M. A., Chen S. H., Woo S. L., Roop D. R. Inhibition of melanoma growth by adenoviral-mediated HSV thymidine kinase gene transfer in vivo. J Invest Dermatol. 1995 Mar;104(3):313–317. doi: 10.1111/1523-1747.ep12664614. [DOI] [PubMed] [Google Scholar]
  4. Brody S. L., Jaffe H. A., Han S. K., Wersto R. P., Crystal R. G. Direct in vivo gene transfer and expression in malignant cells using adenovirus vectors. Hum Gene Ther. 1994 Apr;5(4):437–447. doi: 10.1089/hum.1994.5.4-437. [DOI] [PubMed] [Google Scholar]
  5. Caruso M., Panis Y., Gagandeep S., Houssin D., Salzmann J. L., Klatzmann D. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7024–7028. doi: 10.1073/pnas.90.15.7024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chen S. H., Shine H. D., Goodman J. C., Grossman R. G., Woo S. L. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3054–3057. doi: 10.1073/pnas.91.8.3054. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Culver K. W., Ram Z., Wallbridge S., Ishii H., Oldfield E. H., Blaese R. M. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 1992 Jun 12;256(5063):1550–1552. doi: 10.1126/science.1317968. [DOI] [PubMed] [Google Scholar]
  8. Engelhardt J. F., Yang Y., Stratford-Perricaudet L. D., Allen E. D., Kozarsky K., Perricaudet M., Yankaskas J. R., Wilson J. M. Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses. Nat Genet. 1993 May;4(1):27–34. doi: 10.1038/ng0593-27. [DOI] [PubMed] [Google Scholar]
  9. Freeman S. M., Abboud C. N., Whartenby K. A., Packman C. H., Koeplin D. S., Moolten F. L., Abraham G. N. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993 Nov 1;53(21):5274–5283. [PubMed] [Google Scholar]
  10. Georges R. N., Mukhopadhyay T., Zhang Y., Yen N., Roth J. A. Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res. 1993 Apr 15;53(8):1743–1746. [PubMed] [Google Scholar]
  11. Golumbek P. T., Lazenby A. J., Levitsky H. I., Jaffee L. M., Karasuyama H., Baker M., Pardoll D. M. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 1991 Nov 1;254(5032):713–716. doi: 10.1126/science.1948050. [DOI] [PubMed] [Google Scholar]
  12. Hasegawa Y., Emi N., Shimokata K., Abe A., Kawabe T., Hasegawa T., Kirioka T., Saito H. Gene transfer of herpes simplex virus type I thymidine kinase gene as a drug sensitivity gene into human lung cancer cell lines using retroviral vectors. Am J Respir Cell Mol Biol. 1993 Jun;8(6):655–661. doi: 10.1165/ajrcmb/8.6.655. [DOI] [PubMed] [Google Scholar]
  13. Kozarsky K. F., Wilson J. M. Gene therapy: adenovirus vectors. Curr Opin Genet Dev. 1993 Jun;3(3):499–503. doi: 10.1016/0959-437x(93)90126-a. [DOI] [PubMed] [Google Scholar]
  14. Moolten F. L., Wells J. M. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst. 1990 Feb 21;82(4):297–300. doi: 10.1093/jnci/82.4.297. [DOI] [PubMed] [Google Scholar]
  15. Moolten F. S., Wells J. M., Mroz P. J. Multiple transduction as a means of preserving ganciclovir chemosensitivity in sarcoma cells carrying retrovirally transduced herpes thymidine kinase genes. Cancer Lett. 1992 Jul 10;64(3):257–263. doi: 10.1016/0304-3835(92)90051-v. [DOI] [PubMed] [Google Scholar]
  16. Mullen C. A., Kilstrup M., Blaese R. M. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):33–37. doi: 10.1073/pnas.89.1.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Mulligan R. C. The basic science of gene therapy. Science. 1993 May 14;260(5110):926–932. doi: 10.1126/science.8493530. [DOI] [PubMed] [Google Scholar]
  18. O'Malley B. W., Jr, Chen S. H., Schwartz M. R., Woo S. L. Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res. 1995 Mar 1;55(5):1080–1085. [PubMed] [Google Scholar]
  19. Paul S., Dummer S. Topics in clinical pharmacology: ganciclovir. Am J Med Sci. 1992 Oct;304(4):272–277. doi: 10.1097/00000441-199210000-00010. [DOI] [PubMed] [Google Scholar]
  20. Pilewski J. M., Engelhardt J. F., Bavaria J. E., Kaiser L. R., Wilson J. M., Albelda S. M. Adenovirus-mediated gene transfer to human bronchial submucosal glands using xenografts. Am J Physiol. 1995 Apr;268(4 Pt 1):L657–L665. doi: 10.1152/ajplung.1995.268.4.L657. [DOI] [PubMed] [Google Scholar]
  21. Ram Z., Culver K. W., Walbridge S., Blaese R. M., Oldfield E. H. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 1993 Jan 1;53(1):83–88. [PubMed] [Google Scholar]
  22. Reale F. R., Griffin T. W., Compton J. M., Graham S., Townes P. L., Bogden A. Characterization of a human malignant mesothelioma cell line (H-MESO-1): a biphasic solid and ascitic tumor model. Cancer Res. 1987 Jun 15;47(12):3199–3205. [PubMed] [Google Scholar]
  23. Rusch V. W., Piantadosi S., Holmes E. C. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. J Thorac Cardiovasc Surg. 1991 Jul;102(1):1–9. [PubMed] [Google Scholar]
  24. Setoguchi Y., Jaffe H. A., Chu C. S., Crystal R. G. Intraperitoneal in vivo gene therapy to deliver alpha 1-antitrypsin to the systemic circulation. Am J Respir Cell Mol Biol. 1994 Apr;10(4):369–377. doi: 10.1165/ajrcmb.10.4.8136153. [DOI] [PubMed] [Google Scholar]
  25. Smythe W. R., Kaiser L. R., Hwang H. C., Amin K. M., Pilewski J. M., Eck S. J., Wilson J. M., Albelda S. M. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg. 1994 Jun;57(6):1395–1401. doi: 10.1016/0003-4975(94)90090-6. [DOI] [PubMed] [Google Scholar]
  26. Sorrentino B. P., Brandt S. J., Bodine D., Gottesman M., Pastan I., Cline A., Nienhuis A. W. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science. 1992 Jul 3;257(5066):99–103. doi: 10.1126/science.1352414. [DOI] [PubMed] [Google Scholar]
  27. St Clair M. H., Lambe C. U., Furman P. A. Inhibition by ganciclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information. Antimicrob Agents Chemother. 1987 Jun;31(6):844–849. doi: 10.1128/aac.31.6.844. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Sugarbaker D. J., Heher E. C., Lee T. H., Couper G., Mentzer S., Corson J. M., Collins J. J., Jr, Shemin R., Pugatch R., Weissman L. Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 1991 Jul;102(1):10–15. [PubMed] [Google Scholar]
  29. Weiss L., Orr F. W., Honn K. V. Interactions of cancer cells with the microvasculature during metastasis. FASEB J. 1988 Jan;2(1):12–21. doi: 10.1096/fasebj.2.1.3275560. [DOI] [PubMed] [Google Scholar]
  30. Yang Y., Nunes F. A., Berencsi K., Furth E. E., Gönczöl E., Wilson J. M. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A. 1994 May 10;91(10):4407–4411. doi: 10.1073/pnas.91.10.4407. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES